In addition, the significant delay of EPO therapy in patients with RBV treatment failure likely contributed to a higher number of relevant anemia, RBV dose reduction and, as a consequence, more relapses or an incomplete viral clearance. The gene discussed is EPO; the disease is anemia (phenotype).